Human T-cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia and is also associated with progressive, degenerative neurological disorders referred to as tropical spastic paraparesis or HTLV-I-associated myelopathy (10, 13, 26, 27, 39) . HTLV-I characteristically infects CD4 ϩ T cells in vivo and in vitro (3, 11, 12, (27) (28) (29) . However, HTLV-I-infected B cells and CD8 ϩ T cells have been obtained after culture of peripheral blood mononuclear cells (PBMCs) from infected individuals or after coculture of cord blood lymphocytes or PBMCs with HTLV-I-producing cells (4, 14, 20, 21, 25, 31, 38) . In vitro infections of other cell types, including fibroblasts (2) , endothelial cells (15, 17) , and neural (32) , monocytoid (14) , and microglial (16) cells, have been reported. Cellfree infection with HTLV-I is inefficient compared with that of other retroviruses, and it has been calculated that one in one million virus particles is infectious (5) . Therefore, most studies of HTLV-I infection and T-cell transformation employ cocultivation techniques. It is still unclear whether the virion is unusually labile, is poorly released from the infected cell, or inefficiently binds and penetrates the host cell. Expression of HTLV-I is highly restricted both in vivo and in vitro and is regulated at transcriptional and posttranscriptional levels by inducible, cellular transcription factors and by the products of the viral tax and rex genes (7, 8, 18, 19, (34) (35) (36) 40) .
In addition to obstacles imposed by the biological properties of the virus, molecular genetic studies of HTLV-I infectivity and replication have progressed slowly because of the lack of an infectious molecular clone. Several molecular clones of HTLV-I have been constructed and examined in different laboratories, and some of these have been shown to transiently express mRNAs and proteins in transfected cells (1, 23, 24) ; however, their ability to direct the production of infectious virus particles has not yet been demonstrated. Although genetic defects in the cloned proviruses may abrogate their infectivity, it is more likely that the lack of demonstrable infectivity results from difficulties attributable to (i) poor infectivity intrinsic to HTLV-I virions; (ii) highly restricted expression of the virus in infected cells, which limits both detection and spread of the virus through the cell culture; and (iii) potential cytopathic effects of the virus in productively infected cells. These problems are compounded in the analyses of cloned proviruses since a virus stock generated from transfected cells must be produced in sufficient quantities for subsequent infection experiments. Here, we show that cells transfected with the provirus clone pCS-HTLV released HTLV-I virions that were able to infect primary or transformed T cells in vitro. Furthermore, virus produced by these infected T cells was capable of secondary infections of primary, cultured T cells. pCS-HTLV should therefore prove valuable in future examinations of the biological and biochemical interactions of HTLV-I with the host cell.
pCS-HTLV was constructed by transferring the HTLV-I provirus from a bacteriophage lambda clone containing one of the three proviruses resident in CS-1 cell DNA to a plasmid vector. The transformed T-cell line CS-1 was originally obtained by cocultivation of cord blood lymphocytes with HTLV-I-infected cells from an American adult T-cell leukemia patient (20, 21) . In the process of constructing pCS-HTLV, all flanking cellular DNA was removed; in addition, 30 bp from the 5Ј end and 70 bp from the 3Ј end of the provirus were deleted (these sequences would be regenerated after infection and replication). pCS-HTLV was previously shown by Northern (RNA) blotting, reverse transcription PCR (RT-PCR), and cDNA cloning experiments to direct the synthesis of major and minor viral mRNAs in transiently transfected cells (1) . In addition, functional activities of viral Tax and Rex proteins encoded by pCS-HTLV have been demonstrated (reference 6 and unpublished information). Enzyme-linked immunosorbent assays revealed that p24 gag protein was released into the growth medium shortly after transfection of both HeLa and Two days after transfection of 293 cells in 10-cm-diameter dishes with 10 g of pCS-HTLV, 10 ml of growth medium was collected from one plate and clarified by low-speed centrifugation. Virus was pelleted by centrifugation in a 50Ti rotor at 35,000 rpm for 2 h. The virus pellet was suspended in 0.5 ml of 50 mM Tris-HCl-100 mM KCl-1 mM dithiothreitol, layered on a 15 to 60% sucrose gradient, and centrifuged at 21,000 rpm for 16 h in an SW41 rotor. Fractions of approximately 100 l were collected, and the refractive index was determined for each fraction. Fifty microliters of each fraction was resolved by electrophoresis on a 12% polyacrylamide-SDS gel. After electrophoresis, proteins were electrophoretically transferred to an Immobilon-P (Millipore) polyvinylidene difluoride membrane and incubated with HTLV-I-infected human serum (Scripps) and then with horseradish peroxidase-conjugated goat anti-human immunoglobulin antibody. Specific HTLV-I bands were visualized by chemiluminescent staining (ECL; Amersham). 293 cells with pCS-HTLV; levels of p24 peaked at 2 days posttransfection and decreased with time and cell passage to low but detectable levels (data not shown). To determine whether viral proteins released into the growth medium were assembled into virions, transfected cells and supernatants were examined by electron microscopy (Fig. 1) . HLtat cells (a HeLa cell line expressing human immunodeficiency virus type 1 Tat) were transfected with pCS-HTLV, and 2 days later medium was collected and virus was concentrated by ultracentrifugation; at the same time, cells were collected by scraping, washed with phosphate-buffered saline, and fixed in 1.25% glutaraldehyde. Mature HTLV-I particles were observed both associated with transfected cells (Fig. 1A and B ) and in the supernatant (panel C). The morphology of these particles was identical to that of virus produced from the HTLV-I-infected T-cell line MT2 (panel D). In subsequent experiments human 293 cells were used, since they have a high transfection efficiency and transiently expressed pCS-HTLV at high levels. Supernatant from 293 cells transfected with pCS-HTLV was concentrated by ultracentrifugation, applied to 15 to 60% sucrose density gradients, and centrifuged in an SW41 rotor. Sucrose gradient fractions were then analyzed by electrophoresis on 12% polyacrylamide-sodium dodecyl sulfate (SDS) gels, transferred to polyvinylidene difluoride membranes, and developed with anti-HTLV-I antisera (Fig. 2) . Bands corresponding to HTLV-I p24 gag and p19 gag proteins and gp46 envelope surface glycoprotein were observed with peak intensities centered around fraction 10. Thus, HTLV-I proteins in the supernatant sedimented at a buoyant density of approximately 1.15 gm/ml, characteristic of retrovirus particles. The immunoblot shown in Fig. 2 reveals that the profiles of the gag and env protein bands are not superimposed, reflecting either a loss of envelope during the course of centrifugation or heterogeneity in the virus population related to the extent of virion maturation.
To determine whether the virus particles released into the medium were infectious, 293 cells in 15-cm-diameter plates were transfected with 20 g of pCS-HTLV DNA. Medium was changed 2 days after transfection, and supernatants were collected 1 day later. For each infection, virus was concentrated from one 15-cm-diameter plate of transfected 293 cells. Supernatants were underlaid with 3 ml of a 10% glycerol, and virus was pelleted by centrifugation at 35,000 rpm in a 50Ti rotor for 2 h. Virus pellets were suspended in 0.2 ml of serum-free RPMI 1640 medium containing DEAE-dextran (10 g/ml) and DNase (80 U/ml; Boehringer) for 2 h at 37ЊC. For each cell type infected, a matching virus suspension was incubated at 65ЊC as a negative control. MOLT4 cells, CEM cells, and phytohemagglutinin-interleukin-2-activated cord blood lymphocytes were maintained as previously described (30) . Prior to infection, 10 7 T cells were suspended in 1 ml of RPMI 1640 containing 10 g of DEAE-dextran per ml and mixed with 0.2 ml of virus suspension. Cells and virus were incubated for 2 h at 37ЊC, and then 10 ml of complete medium was added. Infected T cells were collected at various times after infection, and total cellular RNA was extracted, converted to cDNA by reverse transcriptase with random hexamer primers, and then analyzed by PCR amplification. PCR primers that would specifically amplify spliced viral mRNAs were chosen (Fig. 3) ; neither proviral DNA or viral genomic RNA would be amplified under these conditions. Initially, a nested PCR amplification procedure followed by Southern blot analysis of reaction products was used (Fig. 4A ). This two-step process, using primers HT460 and HT7875 for the first reaction and primers HT5050 and HT7356 for the second, specifically amplified the doubly spliced Tax/Rex mRNA. Bands corresponding to the Tax/Rex mRNA, as defined by their size and hybridization to a Tax/Rex probe, were observed after infections of MOLT4 cells, CEM cells, and cord blood lymphocytes. The cDNAs were also examined by single-step PCR amplification in the presence of [ 32 P]dCTP with either HT5050 and HT7356 primers to detect Tax/Rex mRNA or HTex1-2 and HT5275 primers to detect Env mRNA (Fig. 4B and C) . Again, bands of the predicted size were observed in cells infected with virus from pCS-HTLV-transfected 293 cells; no bands were ever observed in cells infected with the heat-inactivated virus preparations. The env-specific primers amplified additional cDNAs in CEM cells, but the virus-specific band was seen only in virus-infected cells (Fig. 4C) . Band intensity was maximal at 2 days after infection and began to decrease at day 4 (data not shown). Thus, de novo viral mRNA synthesis in the infected cells suggested that the virus had successfully completed the early steps of infection, including penetration of the cell, RT, integration, and transcription.
In order to determine whether the infected T cells released infectious virus, MOLT4 cells were infected with cell-free virus from 293 cells transfected with pCS-HTLV as described above.
Two days later, the infected MOLT4 cells were washed three times with complete medium and placed in 3.5-cm-diameter dishes (2 ϫ 10 6 cells per dish). Into each dish was placed a transwell (3-m pore size) containing either cord blood lymphocytes or PBMCs (2 ϫ 10 6 cells) previously activated for 4 days with phytohemagglutinin. An additional set of dishes that contained uninfected MOLT4 cells as negative controls was prepared. This cell culture method allows fluid exchange without cell contact or mixing. Two days after initiation of the transwell cocultures, cells were removed and RNAs were extracted, converted to cDNA, and then PCR amplified with primers specific for either Tax/Rex or Env mRNA as described above. Bands of the predicted size were observed with cDNAs from both cord blood cells and PBMCs cultured in transwells with the infected MOLT4 cells (Fig. 5) . No HTLV-I-specific PCR products were observed in cells cultured with uninfected MOLT4 cells. Thus, the provirus encoded by pCS-HTLV is infectious in secondary infections and therefore competent in both afferent and efferent phases of the infectious cycle.
Cord blood cells from three independent donors were examined for their ability to be transformed with cell-free virus produced from transiently transfected 293 cells. Although infected, none of the cord blood cell cultures proliferated for periods longer than 4 to 6 weeks in the presence of interleukin-2. There are several interpretations of these preliminary results. First, it is possible that the virus titer is simply too low and too few cells were productively infected. It is important to note that T-cell transformation mediated by cell-free preparations of HTLV-I is much less efficient than that mediated by coculture with infected cells (3, 37) . Second, it is possible that pCS-HTLV is infectious but not transforming. We are currently trying several other approaches to infect and transform T cells, including modification of the cell-free infection protocol and development of cells that persistently express pCS-HTLV for transformation mediated by cell contact.
Although molecularly cloned HTLV-I proviruses have been reported to express viral proteins and to release virus-like particles after transfection into cells, their ability to produce infectious virions has not been established. It was therefore the primary objective of these studies to determine whether the virus produced from cells transfected with pCS-HTLV was infectious. The observation that both primary lymphocytes and transformed T-cell lines expressed spliced viral mRNAs after exposure to virus from transiently transfected cells indicated that pCS-HTLV encodes an infectious provirus. Moreover, the ability of infected MOLT4 cells to pass the virus to primary T cells indicated that the virus had successfully completed all steps of the infectious cycle. The cell preferences and kinetics of infection observed here with virus from transfected cells are consistent with results from cell-free infections using virus from MT-2 cells (5). In that report, MOLT4 cells also gave a greater signal (more HTLV-I DNA) than CEM cells after cell-free infection and the signal deteriorated rapidly after infection.
Many fundamental questions pertaining to the biology and biochemistry of HTLV-I have not been addressed because of the lack of an infectious molecular clone. pCS-HTLV now provides a reagent to study the molecular genetics of HTLV-I and to test the effects of mutations in structural and regulatory genes and cis-acting elements on the various stages of the infectious cycle. For example, it should now be possible to directly examine determinants of HTLV-I infection, virion assembly, replication, gene expression, and T-cell transformation. Furthermore, this molecular clone provides a homogeneous source of infectious virus, in contrast to many persistently 
